BioSpace News Archive

Bureau Veritas announced that Rebecca Bratton has been appointed Vice President of Health and Safety in North America, effective immediately.

JW Therapeutics announced that it has received the Investigational New Drug clearance from the National Medical Products Administration of China for a pivotal clinical trial of its anti-CD19 autologous chimeric antigen receptor T cell immunotherapy product Carteyva® in the treatment of second-line large B-Cell lymphoma.

Safety needles can be characterized as an empty bore needle which is considered to decrease or lessen the likelihood of a skin cut harm to the specialist.

Albany NY, United States: A ureteral stent is a peculiarly designed thin hollow tube inserted into the ureter to avert or cure any kind of impediment in the urine flow from the kidney.

Sanofi successfully priced yesterday, March 30, 2022, its offering of a dual-tranche EUR 1.5 billion of notes.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported its results for the full-year ended December 31, 2021 and provided a corporate update.

TILT Biotherapeutics, a clinical-stage biotechnology company developing oncolytic immunotherapy for enabling therapies based on T cells, such as immune checkpoint inhibitors and adoptive cell therapies, announces positive interim progress and safety data from its phase 1 clinical trials in metastatic melanoma and solid tumors.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has received supportive feedback from the U.S. Food & Drug Administration on the Company’s pre-submission package profiling the potential pivotal clinical trial design for ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer.

Rokote Laboratories Finland Ltd., a vaccine development company focussing on a second-generation COVID-19 vaccine, and Exothera S.A. will collaborate to bring the intranasal coronavirus vaccine FINCoVac 2.0 to clinical Phase I/II trials.

Hasten Biopharmaceutic Co., Ltd announced that it has acquired a portfolio of five prescription pharmaceutical products sold in China from Takeda Pharmaceutical Company Limited.